{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:54:21Z","timestamp":1771880061658,"version":"3.50.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:00:00Z","timestamp":1585180800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:00:00Z","timestamp":1585180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00393-020-00768-5","type":"journal-article","created":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T12:03:05Z","timestamp":1585224185000},"page":"241-254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Januskinase-Inhibitoren","Janus kinase inhibitors"],"prefix":"10.1007","volume":"79","author":[{"given":"R.","family":"Alten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mischkewitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-L.","family":"Stefanski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,26]]},"reference":[{"issue":"5","key":"768_CR1","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","volume":"77","author":"S Banerjee","year":"2017","unstructured":"Banerjee\u00a0S et al (2017) JAK-STAT signaling as a\u00a0target for inflammatory and autoimmune diseases: current and future prospects. Drugs 77(5):521\u2013546","journal-title":"Drugs"},{"key":"768_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0092-8674(00)81166-6","volume":"93","author":"SJ Rodig","year":"1998","unstructured":"Rodig\u00a0SJ et al (1998) Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93:373\u2013383","journal-title":"Cell"},{"key":"768_CR3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0092-8674(00)81168-X","volume":"93","author":"H Neubauer","year":"1998","unstructured":"Neubauer\u00a0H et\u00a0al (1998) Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93:397\u2013409","journal-title":"Cell"},{"issue":"1","key":"768_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1600-065X.1994.tb00847.x","volume":"138","author":"WJ Leonard","year":"1994","unstructured":"Leonard\u00a0WJ et al (1994) The molecular basis of X\u2011linked severe combined Immunodeficiency: the role of the Interleukin\u20112 receptor \u03b3 chain as a\u00a0common \u03b3 chain, \u03b3c. Immunol Rev 138(1):61\u201386","journal-title":"Immunol Rev"},{"issue":"11","key":"768_CR5","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1002\/art.40216","volume":"69","author":"LA McIntosh","year":"2017","unstructured":"McIntosh\u00a0LA et al (2017) Genome-wide association meta-analysis reveals novel juvenile idiopathic arthritis susceptibility loci. Arthritis Rheumatol 69(11):2222\u20132232","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"768_CR6","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1007\/s11033-010-0601-5","volume":"38","author":"J-H Tao","year":"2011","unstructured":"Tao\u00a0J\u2011H et al (2011) Meta-analysis of TYK2 gene polymorphisms association with susceptibility to autoimmune and inflammatory diseases. Mol Biol Rep 38(7):4663\u20134672","journal-title":"Mol Biol Rep"},{"issue":"1","key":"768_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1146\/annurev-pathol-012615-044454","volume":"11","author":"J Nangalia","year":"2016","unstructured":"Nangalia\u00a0J, Grinfeld\u00a0J, Green\u00a0AR (2016) Pathogenesis of myeloproliferative disorders. Annu Rev Pathol 11(1):101\u2013126","journal-title":"Annu Rev Pathol"},{"issue":"2","key":"768_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41584-018-0155-9","volume":"15","author":"JJ O\u2019Shea","year":"2019","unstructured":"O\u2019Shea\u00a0JJ, Gadina\u00a0M (2019) Selective Janus kinase inhibitors come of age. Nat Rev Rheumatol 15(2):74\u201375","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"768_CR9","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/rheumatology\/key339","volume":"58","author":"EH Choy","year":"2019","unstructured":"Choy\u00a0EH (2019) Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology 58(6):953\u2013962","journal-title":"Rheumatology"},{"issue":"6","key":"768_CR10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann\u00a0R et al (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N\u00a0Engl J Med 367(6):495\u2013507","journal-title":"N Engl J Med"},{"issue":"9865","key":"768_CR11","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester\u00a0GR et al (2013) Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a\u00a0randomised phase 3 trial. Lancet 381(9865):451\u2013460","journal-title":"Lancet"},{"issue":"4","key":"768_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","volume":"159","author":"J Kremer","year":"2013","unstructured":"Kremer\u00a0J et al (2013) Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a\u00a0randomized trial. Ann Intern Med 159(4):253\u2013261","journal-title":"Ann Intern Med"},{"issue":"6","key":"768_CR13","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven\u00a0RF et\u00a0al (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N\u00a0Engl J Med 367(6):508\u2013519","journal-title":"N Engl J Med"},{"issue":"25","key":"768_CR14","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee\u00a0EB et\u00a0al (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N\u00a0Engl J Med 370(25):2377\u20132386","journal-title":"N Engl J Med"},{"issue":"10093","key":"768_CR15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann\u00a0R et al (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a\u00a0phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet 390(10093):457\u2013468","journal-title":"Lancet"},{"issue":"3","key":"768_CR16","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D van der Heijde","year":"2013","unstructured":"van der Heijde\u00a0D et al (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a\u00a0twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65(3):559\u2013570","journal-title":"Arthritis Rheum"},{"key":"768_CR17","unstructured":"FDA Approves Xeljanz Drugs.com. https:\/\/www.drugs.com\/newdrugs\/fda-approves-xeljanz-rheumatoid-arthritis-3558.html. Zugegriffen: 30. Aug. 2019"},{"key":"768_CR18","unstructured":"Xeljanz. European Medicines Agency https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xeljanz#authorisation-details-section. Zugegriffen: 30. Aug. 2019"},{"issue":"1","key":"768_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","volume":"21","author":"J Wollenhaupt","year":"2019","unstructured":"Wollenhaupt\u00a0J et al (2019) Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a\u00a0global, open-label, long-term extension study. Arthritis Res Ther 21(1):89","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"768_CR20","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann\u00a0R et al (2017) Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 69(3):506\u2013517","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"768_CR21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados\u00a0M et al (2017) Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 76(1):88\u201395","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"768_CR22","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor\u00a0PC et\u00a0al (2017) Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N\u00a0Engl J Med 376(7):652\u2013662","journal-title":"N Engl J Med"},{"issue":"13","key":"768_CR23","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese\u00a0MC et\u00a0al (2016) Baricitinib in patients with refractory rheumatoid arthritis. N\u00a0Engl J Med 374(13):1243\u20131252","journal-title":"N Engl J Med"},{"issue":"1","key":"768_CR24","doi-asserted-by":"publisher","first-page":"e000410","DOI":"10.1136\/rmdopen-2016-000410","volume":"3","author":"P Emery","year":"2017","unstructured":"Emery\u00a0P et al (2017) Patient-reported outcomes from a\u00a0phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis. RMD Open 3(1):e410","journal-title":"RMD Open"},{"issue":"4","key":"768_CR25","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1136\/annrheumdis-2016-209821","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen\u00a0JS et al (2017) Patient-reported outcomes from a\u00a0randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Ann Rheum Dis 76(4):694\u2013700","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"768_CR26","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s13075-017-1410-1","volume":"19","author":"M Schiff","year":"2017","unstructured":"Schiff\u00a0M et al (2017) Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Res Ther 19(1):208","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"768_CR27","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1136\/annrheumdis-2017-211259","volume":"76","author":"EC Keystone","year":"2017","unstructured":"Keystone\u00a0EC et al (2017) Patient-reported outcomes from a\u00a0phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. Ann Rheum Dis 76(11):1853\u20131861","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"768_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1136\/annrheumdis-2018-213271","volume":"78","author":"T Takeuchi","year":"2019","unstructured":"Takeuchi\u00a0T et\u00a0al (2019) Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a\u00a0prospective study. Ann Rheum Dis 78(2):171\u2013178","journal-title":"Ann Rheum Dis"},{"key":"768_CR29","unstructured":"Drugs.com (2019) FDA approves olumiant. https:\/\/www.drugs.com\/newdrugs\/fda-approves-olumiant-baricitinib-2-mg-adults-moderately-severely-active-rheumatoid-arthritis-4760.html. Zugegriffen: 30. Aug. 2019"},{"key":"768_CR30","unstructured":"Olumiant. European Medicines Agency (2019) https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/olumiant. Zugegriffen: 30. Aug. 2019"},{"issue":"8","key":"768_CR31","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s40265-019-01131-y","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham\u00a0A, Keam Peficitinib\u00a0SJ (2019) Peficitinib: first global approval. Drugs 79(8):887\u2013891","journal-title":"Drugs"},{"key":"768_CR32","doi-asserted-by":"crossref","unstructured":"Takeuchi T et al (2019) Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a\u00a0phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann Rheum Dis 78(10):1305\u20131319","DOI":"10.1136\/annrheumdis-2019-215164"},{"key":"768_CR33","doi-asserted-by":"crossref","unstructured":"Tanaka Y et al (2019) Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a\u00a0randomised, double-blind, placebo-controlled phase III trial (RAJ3). Ann Rheum Dis 78(10):1320\u20131332","DOI":"10.1136\/annrheumdis-2019-215163"},{"issue":"4","key":"768_CR34","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","volume":"322","author":"MC Genovese","year":"2019","unstructured":"Genovese\u00a0MC et al (2019) Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA 322(4):315\u2013325","journal-title":"JAMA"},{"issue":"1","key":"768_CR35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13075-018-1541-z","volume":"20","author":"M Genovese","year":"2018","unstructured":"Genovese\u00a0M et al (2018) Effect of filgotinib, a\u00a0selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes. Arthritis Res Ther 20(1):57","journal-title":"Arthritis Res Ther"},{"issue":"10139","key":"768_CR36","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester\u00a0GR et al (2018) Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a\u00a0randomised, double-blind, placebo-controlled phase 3 trial. Lancet 391(10139):2503\u20132512","journal-title":"Lancet"},{"issue":"10188","key":"768_CR37","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen\u00a0JS et al (2019) Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a\u00a0randomised, placebo-controlled, double-blind phase 3 study. Lancet 393(10188):2303\u20132311","journal-title":"Lancet"},{"issue":"10139","key":"768_CR38","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese\u00a0MC et al (2018) Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a\u00a0double-blind, randomised controlled phase 3 trial. Lancet 391(10139):2513\u20132524","journal-title":"Lancet"},{"key":"768_CR39","doi-asserted-by":"crossref","unstructured":"Fleischmann RM et\u00a0al (2019) Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol 71:1788\u2013 1800","DOI":"10.1002\/art.41032"},{"key":"768_CR40","doi-asserted-by":"crossref","unstructured":"Fleischmann RM et\u00a0al (2019) Safety and effectiveness of upadacitinib or adalimumab plus methotexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis","DOI":"10.1136\/annrheumdis-2019-215764"},{"issue":"Suppl 2","key":"768_CR41","first-page":"376","volume":"78","author":"R v. Vollenhoven","year":"2019","unstructured":"v. Vollenhoven\u00a0R et al (2019) THU0197 monotherapy with upadacitinib in MTX-Na\u00efve patients with rheumatoid arthritis: results at 48 weeks from the select-early study. Ann Rheum Dis 78(Suppl 2):376\u2013377","journal-title":"Ann Rheum Dis"},{"key":"768_CR42","unstructured":"FDA Approves Rinvoq (2019) Drug.com, https:\/\/www.drugs.com\/history\/rinvoq.html. Zugegriffen: 30. Aug. 2019"},{"key":"768_CR43","unstructured":"Rinvoq (2019) European Medicines Agency, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rinvoq#authorisation-details-section. Zugegriffen: 21. M\u00e4rz 2020"},{"issue":"8","key":"768_CR44","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/1346-8138.13258","volume":"43","author":"A Asahina","year":"2016","unstructured":"Asahina\u00a0A et al (2016) Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study. J\u00a0Dermatol 43(8):869\u2013880","journal-title":"J Dermatol"},{"issue":"16","key":"768_CR45","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease\u00a0P et\u00a0al (2017) Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N\u00a0Engl J Med 377(16):1537\u20131550","journal-title":"N Engl J Med"},{"issue":"16","key":"768_CR46","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman\u00a0D et\u00a0al (2017) Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N\u00a0Engl J Med 377(16):1525\u20131536","journal-title":"N Engl J Med"},{"key":"768_CR47","unstructured":"Drugs.com (2019) Pfizer announces FDA approval of Xeljanz (tofacitinib) and Xeljanz XR for the treatment of active psoriatic arthritis. https:\/\/www.drugs.com\/newdrugs\/pfizer-announces-fda-approval-xeljanz-tofacitinib-xeljanz-xr-active-psoriatic-arthritis-4677.html. Zugegriffen: 30. Aug. 2019"},{"issue":"10162","key":"768_CR48","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","volume":"392","author":"P Mease","year":"2018","unstructured":"Mease\u00a0P et al (2018) Efficacy and safety of filgotinib, a\u00a0selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a\u00a0randomised, placebo-controlled, phase 2 trial. Lancet 392(10162):2367\u20132377","journal-title":"Lancet"},{"key":"768_CR49","unstructured":"ClinicalTrials.gov (2019) janus kinase inhibitor | Spondyloarthritis\u2014List Results. https:\/\/clinicaltrials.gov\/ct2\/results?cond=Spondyloarthritis&term=janus+kinase+inhibitor&cntry=&state=&city=&dist. Zugegriffen: 30. Aug. 2019"},{"issue":"8","key":"768_CR50","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde\u00a0D et al (2017) Tofacitinib in patients with ankylosing spondylitis: a\u00a0phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis 76(8):1340\u20131347","journal-title":"Ann Rheum Dis"},{"issue":"10162","key":"768_CR51","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde\u00a0D et al (2018) Efficacy and safety of filgotinib, a\u00a0selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a\u00a0randomised, placebo-controlled, phase 2 trial. Lancet 392(10162):2378\u20132387","journal-title":"Lancet"},{"key":"768_CR52","unstructured":"A Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis ( SELECT Axis 1 ) (SELECT Axis 1). ClinicalTrials.gov, Z.a. Zugegriffen: 30. Aug. 2019"},{"issue":"18","key":"768_CR53","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn\u00a0WJ et\u00a0al (2017) Tofacitinib as induction and maintenance therapy for ulcerative colitis. N\u00a0Engl J Med 376(18):1723\u20131736","journal-title":"N Engl J Med"},{"issue":"2","key":"768_CR54","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/ecco-jcc\/jjx133","volume":"12","author":"J Panes","year":"2018","unstructured":"Panes\u00a0J et al (2018) Tofacitinib in patients with ulcerative colitis: health-related quality of life in phase 3 randomised controlled induction and maintenance studies. J\u00a0Crohns Colitis 12(2):145\u2013156","journal-title":"J Crohns Colitis"},{"key":"768_CR55","unstructured":"Drugs.com (2019) Pfizer Announces U.S. FDA Approves Xeljanz (tofacitinib) for the Treatment of Moderately to Severely Active Ulcerative Colitis. https:\/\/www.drugs.com\/newdrugs\/pfizer-announces-u-s-fda-approves-xeljanz-tofacitinib-moderately-severely-active-ulcerative-colitis-4756.html. Zugegriffen: 30. Aug. 2019"},{"key":"768_CR56","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte Roter Hand Brief XELJANZ (Tofacitinib). https:\/\/www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RHB\/2019\/rhb-xeljanz2.pdf?__blob=publicationFile&v=4. Zugegriffen: Zugriff: 30. Aug. 2019"},{"issue":"10","key":"768_CR57","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/ecco-jcc\/jjy085","volume":"12","author":"BE Sands","year":"2018","unstructured":"Sands\u00a0BE et al (2018) Peficitinib, an oral Janus Kinase inhibitor, in moderate-to-severe ulcerative colitis: results from a\u00a0randomised, phase 2 study. J\u00a0Crohns Colitis 12(10):1158\u20131169","journal-title":"J Crohns Colitis"},{"key":"768_CR58","unstructured":"ClinicalsTrials.gov (2019) janus kinase inhibitor | Ulcerative Colitis\u2014List Results. https:\/\/clinicaltrials.gov\/ct2\/results?cond=Ulcerative+Colitis&term=janus+kinase+inhibitor&cntry=&state=&city=&dist. Zugegriffen: 30. Aug. 2019"},{"issue":"3","key":"768_CR59","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2015.06.045","volume":"73","author":"LL Levy","year":"2015","unstructured":"Levy\u00a0LL, Urban\u00a0J, King\u00a0BA (2015) Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J\u00a0Am Acad Dermatol 73(3):395\u2013399","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"768_CR60","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/bjd.14871","volume":"175","author":"R Bissonnette","year":"2016","unstructured":"Bissonnette\u00a0R et\u00a0al (2016) Topical tofacitinib for atopic dermatitis: a\u00a0phase IIa randomized trial. Br J Dermatol 175(5):902\u2013911","journal-title":"Br J Dermatol"},{"issue":"4","key":"768_CR61","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","volume":"80","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky\u00a0E et al (2019) Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J\u00a0Am Acad Dermatol 80(4):913\u2013921e9","journal-title":"J Am Acad Dermatol"},{"key":"768_CR62","unstructured":"Lilly\u2019s BREEZE-AD1 & BREEZE-AD2 phase 3 studies of baricitinib in patients with moderate to severe AD meets primary endpoint. Indianapolis: Pharmabiz.com, Z.a. Zugegriffen: 30. Aug. 2019"},{"key":"768_CR63","unstructured":"ClinicalsTrials.gov janus kinase inhibitor | Atopic Dermatitis\u2014List Results. https:\/\/clinicaltrials.gov\/ct2\/results?term=janus+kinase+inhibitor&cond=Atopic+Dermatitis&rank=3&view=results#rowId2. Zugegriffen: 30. Aug. 2019"},{"issue":"10143","key":"768_CR64","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","volume":"392","author":"DJ Wallace","year":"2018","unstructured":"Wallace\u00a0DJ et al (2018) Baricitinib for systemic lupus erythematosus: a\u00a0double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 392(10143):222\u2013231","journal-title":"Lancet"},{"key":"768_CR65","unstructured":"ClinicalTrials.gov (2019) Safety of Tofacitinib, a.O.J.K.I., in Systemic Lupus Erythematosus. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02535689?term=janus+kinase+inhibitor&cond=Systemic+Lupus+Erythematosus&rank=1. Zugegriffen: 28. Aug. 2019"},{"key":"768_CR66","unstructured":"A Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus. ClinicalTrials.gov. Zugegriffen: 30. Aug. 2019"},{"key":"768_CR67","unstructured":"ClinicalTrials.gov (2019) baricitinib | systemic lupus erythematodes\u2014list results. https:\/\/clinicaltrials.gov\/ct2\/results?cond=Systemic+Lupus+Erythematosus&term=baricitinib&cntry=&state=&city=&dist=&Search=Search. Zugegriffen: 30. Aug. 2019"},{"issue":"1","key":"768_CR68","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40744-018-0097-3","volume":"5","author":"S Cohen","year":"2018","unstructured":"Cohen\u00a0S et al (2018) Worldwide, 3\u2011year, post-marketing surveillance experience with tofacitinib in rheumatoid arthritis. Rheumatol Ther 5(1):283\u2013291","journal-title":"Rheumatol Ther"},{"issue":"7","key":"768_CR69","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","volume":"76","author":"SB Cohen","year":"2017","unstructured":"Cohen\u00a0SB et al (2017) Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 76(7):1253\u20131262","journal-title":"Ann Rheum Dis"},{"key":"768_CR70","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s13075-015-0880-2","volume":"17","author":"V Strand","year":"2015","unstructured":"Strand\u00a0V et al (2015) Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther 17:362","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"768_CR71","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","volume":"75","author":"JR Curtis","year":"2016","unstructured":"Curtis\u00a0JR et al (2016) Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis 75(10):1843\u20131847","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"768_CR72","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/art.40189","volume":"69","author":"KL Winthrop","year":"2017","unstructured":"Winthrop\u00a0KL et\u00a0al (2017) Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol 69(10):1960\u20131968","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"768_CR73","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1002\/art.40187","volume":"69","author":"KL Winthrop","year":"2017","unstructured":"Winthrop\u00a0KL et\u00a0al (2017) The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial. Arthritis Rheumatol 69(10):1969\u20131977","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"768_CR74","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3899\/jrheum.171361","volume":"46","author":"JS Smolen","year":"2019","unstructured":"Smolen\u00a0JS et\u00a0al (2019) Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J\u00a0Rheumatol 46(1):7\u201318","journal-title":"J Rheumatol"},{"issue":"1","key":"768_CR75","first-page":"46","volume":"56","author":"H Schulze-Koops","year":"2016","unstructured":"Schulze-Koops\u00a0H et al (2016) Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies. Baillieres Clin Rheumatol 56(1):46\u201357","journal-title":"Baillieres Clin Rheumatol"},{"issue":"14","key":"768_CR76","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1182\/blood-2014-08-596361","volume":"124","author":"RC Skoda","year":"2014","unstructured":"Skoda\u00a0RC (2014) Less \u3008em\u3009Jak2\u3008\/em\u3009 makes more platelets. Blood 124(14):2168\u20132169","journal-title":"Blood"},{"issue":"39","key":"768_CR77","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1093\/eurheartj\/ehx145","volume":"39","author":"A Ogdie","year":"2018","unstructured":"Ogdie\u00a0A et al (2018) Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a\u00a0general population-based cohort study. Eur Heart\u00a0J 39(39):3608\u20133614","journal-title":"Eur Heart J"},{"key":"768_CR78","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nrrheum.2012.184","volume":"8","author":"B Hoppe","year":"2012","unstructured":"Hoppe\u00a0B, D\u00f6rner\u00a0T (2012) Coagulation and the fibrin network in rheumatic disease: a\u00a0role beyond haemostasis. Nat Rev Rheumatol 8:738","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"768_CR79","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","volume":"74","author":"IB McInnes","year":"2015","unstructured":"McInnes\u00a0IB et al (2015) Effect of interleukin\u20116 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a\u00a0randomised, placebo-controlled study. Ann Rheum Dis 74(4):694\u2013702","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"768_CR80","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1136\/annrheumdis-2016-209773","volume":"76","author":"A Strangfeld","year":"2017","unstructured":"Strangfeld\u00a0A et\u00a0al (2017) Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis 76(3):504\u2013510","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"768_CR81","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/acr.23421","volume":"70","author":"X Mariette","year":"2018","unstructured":"Mariette\u00a0X et\u00a0al (2018) Lymphoma in the tofacitinib rheumatoid arthritis clinical development program. Arthritis Care Res 70(5):685\u2013694","journal-title":"Arthritis Care Res"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00768-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-020-00768-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00768-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:31:30Z","timestamp":1616718690000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-020-00768-5"}},"subtitle":["State of the Art im klinischen Einsatz und Zukunftsperspektiven","State of the art in clinical use and future perspectives"],"short-title":[],"issued":{"date-parts":[[2020,3,26]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["768"],"URL":"https:\/\/doi.org\/10.1007\/s00393-020-00768-5","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,26]]},"assertion":[{"value":"26 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"R. Alten gibt an, von AbbVie Vortragshonorare, von Gilead Sciences, Eli Lilly und Pfizer Vortrags- und Beraterhonorare erhalten zu haben. Weiterhin erhielt sie Forschungsunterst\u00fctzung von Gilead Sciences, Eli Lilly und Pfizer. T.\u00a0D\u00f6rner gibt an, von Gilead Sciences Beraterhonorare und von AbbVie und Eli Lilly Vortrags- und Beraterhonorare erhalten zu haben. Weiterhin erhielt er Forschungsunterst\u00fctzung von AbbVie und Eli Lilly. M.\u00a0Mischkewitz und A.\u2011L.\u00a0Stefanski geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}